Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
- PMID:17588546
- DOI: 10.1016/j.biopsych.2007.03.027
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents
Abstract
Background: Recent studies suggest that the treatment of major depressive disorder (MDD) with newer antidepressant drugs that simultaneously enhance norepinephrine and serotonin neurotransmission might result in higher response and remission rates than the selective serotonin reuptake inhibitors (SSRIs). The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs.
Methods: Medline/Pubmed, EMBase, clinical trial registries, program syllabi from major psychiatric meetings held since 1995, and documents from relevant pharmaceutical companies were searched for double-blind, randomized trials comparing a newer serotonergic-noradrenergic antidepressant drug (venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, or moclobemide) with an SSRI for MDD.
Results: Ninety-three trials (n = 17,036) were combined using a random-effects model. Treatment with serotonergic + noradrenergic antidepressant drugs was more likely to result in clinical response than the SSRIs (risk ratio [RR] = 1.059; response rates 63.6% versus 59.3%; p = .003). There was no evidence for heterogeneity among studies combined (p = 1.0). Excluding each individual agent did not significantly alter the pooled RR. With the exception of duloxetine (.985), RRs for response for each individual serotonergic + noradrenergic antidepressant drug were within the 95% confidence interval of the pooled RR (1.019-1.101).
Conclusions: Serotonergic-noradrenergic antidepressant drugs seem to have a modest efficacy advantage compared with SSRIs in MDD. With the Number Needed to Treat (NNT) statistic as one indicator of clinical significance, nearly 24 patients would need to be treated with dual-action antidepressant drugs instead of SSRIs in order to obtain one additional responder. This difference falls well below the mark of NNT = 10 suggested by the United Kingdom's National Institute of Clinical Excellence but nonetheless might be of public health relevance given the large number of depressed patients treated with SSRI /serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant drugs. Further research is needed to examine whether larger differences between classes of antidepressant drugs might exist in specific MDD sub-populations or for specific MDD symptoms.
Similar articles
- A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.Papakostas GI, Fava M.Papakostas GI, et al.Eur Neuropsychopharmacol. 2007 Jan;17(1):32-6. doi: 10.1016/j.euroneuro.2006.05.001. Epub 2006 Jun 8.Eur Neuropsychopharmacol. 2007.PMID:16762534Clinical Trial.
- A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.Papakostas GI, Homberger CH, Fava M.Papakostas GI, et al.J Psychopharmacol. 2008 Nov;22(8):843-8. doi: 10.1177/0269881107083808. Epub 2008 Feb 28.J Psychopharmacol. 2008.PMID:18308801
- Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches.Papakostas GI, Fava M, Thase ME.Papakostas GI, et al.Biol Psychiatry. 2008 Apr 1;63(7):699-704. doi: 10.1016/j.biopsych.2007.08.010. Epub 2007 Oct 24.Biol Psychiatry. 2008.PMID:17919460
- Agomelatine versus other antidepressive agents for major depression.Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M.Guaiana G, et al.Cochrane Database Syst Rev. 2013 Dec 17;2013(12):CD008851. doi: 10.1002/14651858.CD008851.pub2.Cochrane Database Syst Rev. 2013.PMID:24343836Free PMC article.Review.
- A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression.Nelson JC.Nelson JC.Biol Psychiatry. 1999 Nov 1;46(9):1301-8. doi: 10.1016/s0006-3223(99)00173-0.Biol Psychiatry. 1999.PMID:10560035Review.
Cited by
- A brief history of the development of antidepressant drugs: from monoamines to glutamate.Hillhouse TM, Porter JH.Hillhouse TM, et al.Exp Clin Psychopharmacol. 2015 Feb;23(1):1-21. doi: 10.1037/a0038550.Exp Clin Psychopharmacol. 2015.PMID:25643025Free PMC article.Review.
- Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice.Han C, Wang SM, Lee SJ, Jun TY, Pae CU.Han C, et al.Chonnam Med J. 2015 Aug;51(2):66-80. doi: 10.4068/cmj.2015.51.2.66. Epub 2015 Aug 17.Chonnam Med J. 2015.PMID:26306301Free PMC article.Review.
- Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.Franco-Chaves JA, Mateus CF, Luckenbaugh DA, Martinez PE, Mallinger AG, Zarate CA Jr.Franco-Chaves JA, et al.J Affect Disord. 2013 Jul;149(1-3):319-25. doi: 10.1016/j.jad.2013.02.003. Epub 2013 Mar 18.J Affect Disord. 2013.PMID:23517885Free PMC article.Clinical Trial.
- Effect of prenatal administration of venlafaxine on postnatal development of rat offspring.Dubovický M, Császárová E, Brnoliaková Z, Ujházy E, Navarová J, Mach M.Dubovický M, et al.Interdiscip Toxicol. 2012 Jun;5(2):92-7. doi: 10.2478/v10102-012-0016-3.Interdiscip Toxicol. 2012.PMID:23118594Free PMC article.
- Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June HL.Warnock KT, et al.Pharmacol Biochem Behav. 2012 Nov;103(1):111-8. doi: 10.1016/j.pbb.2012.07.014.Pharmacol Biochem Behav. 2012.PMID:22884707Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical